Domperidone

CinRx Pharma Announces Additional $73 Million Financing

Retrieved on: 
Jeudi, mai 30, 2024
Biotechnology, Pharmaceutical, Health, DDW, Patient, Diarrhea, Investigational New Drug, Gastroparesis, Collection, PYY, Obesity, Deudomperidone, IND, Drug development, Safety, Conference, IBS-D, Janssen Pharmaceuticals, Domperidone, Hypertension, IPO, Acquisition, Body composition, Roche, QT, Cinergy, AstraZeneca, Phloroglucinol, Pharmaceutical industry

CinRx Pharma, a hub-and-spoke biotech accelerating high-impact medicines, today announced the closing of a $73 million financing, bringing the total funds raised to $176 million.

Key Points: 
  • CinRx Pharma, a hub-and-spoke biotech accelerating high-impact medicines, today announced the closing of a $73 million financing, bringing the total funds raised to $176 million.
  • In addition to its company creation function, CinRx has forged several CINergy partnerships with existing companies.
  • In early 2023, CinCor was acquired by AstraZeneca in a deal worth $1.3 billion upfront and an additional $500 million in biobucks.
  • CinDome recently raised $40 million in a Series B financing from Perceptive Advisors and CinRx, and is actively enrolling the Phase 2 envision3D study for adults with diabetic gastroparesis, expected to read out in 2025.

CinDome Pharma Announces $40 Million Series B Extension

Retrieved on: 
Jeudi, mai 16, 2024
Health, General Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Partnership, Diabetes, Gastroparesis, Food, Nausea, FDA, Domperidone, Incidence, Venture round, Vomiting, Pharmaceutical industry

CinDome Pharma, a CinRx portfolio company dedicated to advancing a safe, chronic therapy for gastroparesis, today announced a $40 million Series B financing extension.

Key Points: 
  • CinDome Pharma, a CinRx portfolio company dedicated to advancing a safe, chronic therapy for gastroparesis, today announced a $40 million Series B financing extension.
  • The additional funds from existing investors, including Perceptive Advisors and CinRx Pharma, bring the Series B raise total to $59 million.
  • The capital will support the ongoing enrollment and evaluation of deudomperidone in the Phase 2 envision3D study in adults with diabetic gastroparesis and position the company for registrational trials.
  • “We are grateful for the continued support and partnership from Perceptive Advisors to advance this high-impact therapeutic and bring a new hope to people impacted by gastroparesis.”

CinRx Portfolio Company CinDome Pharma Presents Encouraging Data on Deudomperidone (CIN-102) at 2023 Digestive Disease Week® Conference

Retrieved on: 
Lundi, mai 8, 2023
Health, Other Science, Clinical Trials, General Health, Research, Science, Abstract, Gastrointestinal disease, ASGE, Society, Gastroenterology, American Gastroenterological Association, Half-life, Disease, American Society for Gastrointestinal Endoscopy, SSAT, FACC, Clinical trial, ECG, Gastrointestinal Endoscopy, American Association for the Study of Liver Diseases, Cmax, Medicine, Endoscopy, QT, AASLD, Extrapyramidal system, DDW, Gastroparesis, AGA, Patient, Domperidone, Physician, Risk, Hepatology, Poster, Ageing, Metoclopramide, Conference, Pharmaceutical industry, Deudomperidone

CinDome Pharma, a CinRx portfolio company, presented a poster at the 2023 Digestive Disease Week (DDW) Conference titled “Effect of Therapeutic and Supratherapeutic Doses of Deudomperidone (CIN-102) on Cardiac Repolarization in a Thorough QT (TQT) Study in Healthy Subjects.” The poster highlighted data evaluating deudomperidone, a modified formulation of domperidone, for the long-term treatment of gastroparesis.

Key Points: 
  • CinDome Pharma, a CinRx portfolio company, presented a poster at the 2023 Digestive Disease Week (DDW) Conference titled “Effect of Therapeutic and Supratherapeutic Doses of Deudomperidone (CIN-102) on Cardiac Repolarization in a Thorough QT (TQT) Study in Healthy Subjects.” The poster highlighted data evaluating deudomperidone, a modified formulation of domperidone, for the long-term treatment of gastroparesis.
  • The study presented at DDW assessed the effect of deudomperidone on electrocardiogram (ECG) parameters, including concentration-QTc (C-QTc) analysis.
  • The data demonstrated the potential of deudomperidone to decrease the risk of QT prolongation associated with the traditional formulation of domperidone.
  • Deudomperidone is being developed by CinDome as the first line therapy for chronic gastroparesis, which impacts an estimated 16 million people in the U.S.

CinRx’s CinDome Pharma to Present a Poster on Deudomperidone (CIN-102) at 2023 Digestive Disease Week® Conference

Retrieved on: 
Mardi, mai 2, 2023
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Abstract, Gastrointestinal disease, US Food Sovereignty Alliance, ASGE, Society, Gastroenterology, American Gastroenterological Association, Disease, American Society for Gastrointestinal Endoscopy, SSAT, Food and Drug Administration, Gastrointestinal Endoscopy, American Association for the Study of Liver Diseases, Medicine, Gastroparesis, Endoscopy, QT, AASLD, Extrapyramidal system, DDW, Domperidone, AGA, Physician, Hepatology, Poster, Metoclopramide, Conference, Food, Pharmaceutical industry, Deudomperidone

CinDome Pharma, a CinRx portfolio company, will present a poster at the 2023 Digestive Disease Week (DDW) Conference, held May 6th – 9th in Chicago, Illinois.

Key Points: 
  • CinDome Pharma, a CinRx portfolio company, will present a poster at the 2023 Digestive Disease Week (DDW) Conference, held May 6th – 9th in Chicago, Illinois.
  • The poster, titled “Effect of Therapeutic and Supratherapeutic Doses of Deudomperidone (CIN-102) on Cardiac Repolarization in a Thorough QT (TQT) Study In Healthy Subjects” will highlight data on the promise of deudomperidone for the long-term management of gastroparesis.
  • Gastroparesis impacts an estimated 16 million people in the US and has suboptimal existing treatment options.
  • The meeting showcases more than 3,100 abstracts and hundreds of lectures on the latest advances in GI research, medicine and technology.

CinRx Pharma Announces First Participant Dosed in CinDome’s Phase 2 Study of Deudomperidone (CIN-102) for the Treatment of Diabetic Gastroparesis

Retrieved on: 
Jeudi, avril 27, 2023
Biotechnology, Diabetes, Health, Pharmaceutical, Clinical Trials, Dopamine, Gastroparesis, QT, Vomiting, Patient, Domperidone, Risk, Nausea, Bloating, Trial of the century, Safety, Syndrome, Deudomperidone, Pharmaceutical industry

CinRx Pharma, a mosaic of biotechnology companies accelerating transformational new medicines to patients, today announced that the first study participant has been dosed in CinDome Pharma’s Phase 2 envision3D study of deudomperidone (CIN-102) in patients with diabetic gastroparesis.

Key Points: 
  • CinRx Pharma, a mosaic of biotechnology companies accelerating transformational new medicines to patients, today announced that the first study participant has been dosed in CinDome Pharma’s Phase 2 envision3D study of deudomperidone (CIN-102) in patients with diabetic gastroparesis.
  • Deudomperidone is a Dopamine 2/3 antagonist with prokinetic and antiemetic effects being evaluated for the chronic treatment of patients who currently have no therapeutic options for long term management.
  • Gastroparesis is a syndrome defined by delayed gastric emptying in the absence of any physical obstruction and symptoms include bloating, nausea, vomiting, postprandial fullness, and early satiety.
  • “Deudomperidone is a novel formulation of domperidone which we have designed to overcome the limitations of existing therapies.

CinDome Pharma announces successful completion of thorough QT study of CIN-102 (deudomperidone) in healthy subjects.

Retrieved on: 
Mardi, janvier 25, 2022
Food, Heart rate, Deuterium, Dopamine, Risk, Volunteering, Clinical trial, Plasma, QT, IPO, Degenerative disease, Domperidone, Wireless ambulatory ECG, Diabetes, FACC, ECG, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Patient, Gastroparesis, GLOBE, FDA, Fine chemical, Pharmaceutical industry

Domperidone has been associated with an increased risk of QT prolongation and it has not received marketing authorization in the United States.

Key Points: 
  • Domperidone has been associated with an increased risk of QT prolongation and it has not received marketing authorization in the United States.
  • Results of this study confirm a potential path to the first approval of a deudomperidone therapeutic in the United States.
  • CINCINNATI, Jan. 25, 2022 (GLOBE NEWSWIRE) -- CinDome Pharma, Inc. (CinDome), a clinical-stage biopharmaceutical company and member of the CinRx Pharma portfolio, today announced the negative results of a clinical thorough QT/QTc study of CIN-102 (deudomperidone) in healthy individuals.
  • CinDome Pharma, a subsidiary of CinRx Pharma, is a biopharmaceutical company focused on the development of CIN-102 (deudomperidone) to treat patients with gastrointestinal disorders.

CinDome Pharma Announces Start of Phase 2 Trial of Deuterated Domperidone (CIN-102)

Retrieved on: 
Jeudi, septembre 19, 2019
Digestive diseases, Medical specialties, Drugs, Chloroarenes, Antiemetics, Benzimidazoles, Domperidone, Janssen Pharmaceutica, Ureas, Gastroparesis

CINCINNATI, Sept. 19, 2019 (GLOBE NEWSWIRE) -- CinDome Pharma, Inc. (CinDome), a company whose lead product is deuterated domperidone (CIN-102), today announced that is has enrolled the first patient in a Phase 2 clinical trial of CIN-102.

Key Points: 
  • CINCINNATI, Sept. 19, 2019 (GLOBE NEWSWIRE) -- CinDome Pharma, Inc. (CinDome), a company whose lead product is deuterated domperidone (CIN-102), today announced that is has enrolled the first patient in a Phase 2 clinical trial of CIN-102.
  • Non-deuterated domperidone is a well-known D2/D3 receptor antagonist used in many parts of the world for the treatment of nausea and vomiting and gastroparesis.
  • CinDome has completed two Phase 1 studies and is now initiating its Phase 2 programs.
  • CinDome Pharma, a subsidiary of CinRx Pharma, is a biopharmaceutical company focused on the development of products to treat gastrointestinal disorders.